NEW YORK, NY / ACCESSWIRE / October 2, 2017 / In the biotech world, it's often a race between pharma companies to get to the finish line with their drug candidates faster than others. Shares of GW Pharmaceuticals tanked on Friday after a small rival company called Zogenix nearly tripled in price after reporting positive study results on its epilepsy drug ZX008.

RDI Initiates Coverage on:

GW Pharmaceuticals plc
http://www.rdinvesting.com/report/?ticker=GWPH

Zogenix, Inc.
http://www.rdinvesting.com/report/?ticker=ZGNX

GW Pharmaceuticals' plc shares closed down 9.60% this past Friday on explosive trading volume compared to usual. The stock saw its shares drop after rival company Zogenix reported positive results in a study on a drug that is used to treat Dravet syndrome, a severe epilepsy syndrome. Traders have been eagerly watching GW Pharma and its Epidiolex lead candidate drug to fight epilepsy syndromes including Dravet Syndrome. The fact that Zogenix has reported such positive results could lead to their drug candidate hitting the market sooner which left traders feeling uncertain over this competition that GW now has.

Access RDI?s GW Pharmaceuticals plc Research Report at:
http://www.rdinvesting.com/report/?ticker=GWPH

Zogenix, Inc.'s shares were on a rocket this past Friday, closing the day up nearly 172%. The stock hit a new high of $37.55 after revealing epilepsy drug study results that were positive. The pharma company almost tripled in value in one trading day after revealing that the Phase 3 study of its ZX008, a drug used to treat Dravet syndrome, had met its primary endpoint. In a study that included 119 patients of adults and children, one dosage group out of three had seen a 64% reduction in monthly convulsive seizures in comparison to the placebo. The company's CEO Stephen Farr has said the company is on "track to submit applications for regulatory approvals in the U.S. and Europe in the second half of 2018." The director of the Pediatric Epilepsy Center in UCSF Benioff Children's Hospital San Francisco, Joseph Sullivan M.D, stated, "These results are truly exciting and demonstrate, in a large multicenter controlled trial, the impressive efficacy of low-dose fenfluramine for patients with Dravet syndrome."

Access RDI?s Zogenix, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=ZGNX

Our Actionable Research on GW Pharmaceuticals plc (NASDAQ: GWPH) and Zogenix, Inc. (NASDAQ: ZGNX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com